Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

被引:1
|
作者
Lee, Ji Yae [1 ]
Kim, Sue [2 ]
Lee, Yaeji [3 ]
Kwon, Yu-Jin [4 ]
Lee, Ji-Won [1 ,5 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Family Med, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Severance Hosp, Int Hlth Care Ctr, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Biostat & Comp, Seoul 03722, South Korea
[4] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Family Med, Yongin 16995, South Korea
[5] Yonsei Univ, Severance Hosp, Dept Family Med, Coll Med,Inst Innovat Digital Healthcare, Yonsei Ro 50-1, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Mediterranean diet adherence; steatotic liver disease; metabolic dysfunction-associated steatotic liver disease; alcohol-related liver disease; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; GUIDELINE; BENEFITS; NOMENCLATURE; NUTRITION; HEALTH;
D O I
10.3390/nu16203551
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and Aims: Metabolic liver disease is associated with obesity, insulin resistance, cardiovascular disease, and metabolic disorders. A Mediterranean diet (MD), known for its anti-inflammatory and antioxidant properties, is effective in managing various chronic diseases, including liver diseases. This study aimed to explore the influence of adherence to the MD on the risk of chronic metabolic diseases, including steatotic liver disease (SLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related liver diseases (ALDs). Methods: This retrospective cohort study analyzed 5395 individuals from a single center between 2020 and 2022, grouped by adherence to the MD using the Korean Mediterranean Diet Adherence Score (K-MEDAS). MASLD score, ALD, and cardiovascular risk factors were also assessed. Statistical analyses were performed using 1:1 exact matching and multiple regression to compare the less adherent (K-MEDAS 0-7) and highly adherent (K-MEDAS 8-13) groups. Results: Adjusting for confounding variables, high adherence to the MD was significantly associated with lower rates of SLD (odds ratio [OR] 0.818, 95% confidence interval [CI] 0.700-0.957, p = 0.012), MASLD (OR 0.839, 95% CI 0.714-0.986, p = 0.033), and ALD (OR 0.677, 95% CI 0.671-0.683, p < 0.001). Post-propensity score matching analysis revealed that the highly adherent group exhibited significantly lower triglyceride levels, triglyceride and glucose index, atherogenic Index of Plasma, and Framingham risk scores than the less adherent group. Conclusions: Good adherence to the MD considerably reduces the risk of SLD, MASLD, and ALD, underscoring its protective effects and potential to prevent metabolic liver diseases and their complications.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [32] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [33] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [34] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [35] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [36] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [37] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [38] A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction-associated steatotic liver disease
    Grinshpan, Laura S.
    Haim, Yaara Even
    Ivancovsky-Wajcman, Dana
    Fliss-Isakov, Naomi
    Nov, Yuval
    Webb, Muriel
    Shibolet, Oren
    Kariv, Revital
    Zelber-Sagi, Shira
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [39] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [40] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)